Four Pillars Oncology Program

The Noxopharm candidate Veyonda® is being investigated for activity against cancer and in inflammation and septic shock / COVID-19.

The Noxopharm 4-pillar strategy for Veyonda® in cancer aims to prove that adding Veyonda® to standard cancer treatments will enhance the effectiveness of:

  • Externally delivered radiation (DARRT)

  • Internally delivered radiation (LuPIN)

  • Checkpoint inhibitors (IONIC)

  • Chemotherapy (CEP)

Veyonda® is currently not approved in Australia or any other country